NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW) today announced that Theodore Zucconi, Ph.D., President, Pro-Pharmaceuticals, is scheduled to present a corporate update at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008 at 4:05 pm to be held at The New York Palace Hotel in New York City. Dr. Zucconi plans to discuss the regulatory pathway to filing a New Drug Application (“NDA”) for the Company’s lead drug candidate DAVANAT®. The Company has a pre-NDA meeting scheduled with the U.S. Food & Drug Administration on December 22nd for DAVANAT® to be co-administered with 5-FU to treat late-stage colorectal cancer patients.
